自閉症に対するｓｅｃｒｅｔｉｎの有効性に関する研究

• 東田 好広

  徳島大学医学部発生発達医学講座小児医学分野

• 森 健治

  徳島大学医学部発生発達医学講座小児医学分野

• 橋本 俊顕

  鳴門教育大学学校教育学部障害児教育

• 宮崎 雅仁

  徳島大学医学部発生発達医学講座小児医学分野

• 黒田 泰弘

  徳島大学医学部発生発達医学講座小児医学分野

書誌事項

タイトル別名

• Efficacy of Secretin for the Treatment of Autism

抄録

We administered secretin intravenously to 14 patients with autism (9 to 14 years, 10 males; 4 females), and evaluated its clinical effect. We also measured cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and 5-hydroxy-indole-3-acetic acid (5HIAA) before and after 4 weeks treatment, and compared them with the grade of improvement of the clinical symptoms assessed by the scores of Autism Diagnostic Interview-Revised (ADI-R). After injection of secretin, the ADI-R score increased in 8 patients, but declined in 3. Improvement was observed in functions such as sociability (interpersonal relationships), communication and speech improved, whereas in the others, symptoms such as hyperkinesias and stereotyped behavior became worse. The CSF levels of HVA was significantly increased in all of the patients showing an improvement in the ADI-R score. 5HIAA levels also tended to increase, although this increase was not significant. These findings suggest that secretin promotes the metabolism of serotonin and dopamine in the central nervous system, which may contribute to improvement in clinical symptoms of autism.

収録刊行物

• 脳と発達

  脳と発達 36 (4), 289-295, 2004

  THE JAPANESE SOCIETY OF CHILD NEUROLOGY

キーワード

• 自閉症
• セロトニン
• ドーパミン
• ADI-R

詳細情報

• CRID: 1390001204553750272
• NII論文ID: 10013764612
• NII論文ID: 130004183689
• NII書誌ID: AN0020232X
• DOI: 10.11251/ojjscn1969.36.289
• ISSN: 18847668
• ISSN: 00290831
• PubMed: 15272612
• Web Site: https://search.jamas.or.jp/link/ui/2004272920
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • PubMed
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可